Pharming Group N.V. announces encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland.

Pharming Group N.V. invites its shareholders to the 2020 Annual General Meeting (AGM) to be held at 14:00 CET on 20 May 2020

Call slides now available for download.

Annual Report 2019 is available for download on the Pharming website today

Pharming Group N.V. announces the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension of the indication for RUCONEST® to the European Commission.

Pharming Group N.V. announces that it has been included in the Euronext Amsterdam Midkap index (AMX).

Pharming Group N.V. today announced that its Chief Financial Officer, Robin Wright, has decided (for family reasons) not to put himself up for re-election as a member of the Board of Management and thus as Chief Financial Officer at the upcoming General Meeting of Shareholders on 20 May 2020 and that, as result of this decision, his term with the Company will end as at that date.

Pharming Group N.V. today announced it has also received US Food and Drug Administration (FDA) approval of Pharming’s Prior Approval Supplement to add the new Netherlands production facility of starting material to the Biologics License Application (BLA) to support its lead product, RUCONEST®.

The Company will hold a conference call at 13.00 CET/07.00 EST today. Dial in details can be found on page 12 of the press release.

Pharming Group N.V. today announced it has received European Medicines Agency (EMA) approval of a Type II Variation for a new production facility for its lead product, RUCONEST®.